About Us
Company Highlights/Strategic Advantages
- Lead Product Candidate Targets Large Markets with No Competition: Our lead product candidate, MQX-503, for the prevention and treatment of Raynaud’s Disease/Phenomenon, targets large, underserved markets and utilizes the unique benefits of our TAM™delivery technology enabling us to successfully address unmet patient needs.
- Launch Preparation Underway for Lead Product: We submitted our NDA for our lead product, MQX-503, for the prevention and treatment of Raynaud’s, which was accepted for filing in June 2008. Approximately six months after the U.S. filing, we intend to begin the registration process in Europe.
- Unique, Proprietary Platform Technology Producing a Deep, Product Pipeline: Our unique proprietary TAM drug delivery technology is broadly applicable and capable of rapid local delivery of either hydrophilic or hydrophobic therapeutic agents through thickened skin and nails to the site of inflammation or infection.
- Strong Intellectual Property Position: Our 17 issued patents, and 14 patent applications in the U.S., and our 18 issued patents and 128 patent applications outside of the U.S., provide broad intellectual property protection for our product candidates, including our TAM drug delivery system.
- Experienced Leadership with Proven Industry Track Record: Our senior management team collectively has over 170 years of regulatory, product development and commercialization experience in the biopharmaceutical industry. As a group, this management team has taken approximately 26 drugs through development and regulatory approval and has executed the market launch of over 10 pharmaceutical drugs while at other biotechnology and pharmaceutical companies.